Internal Medicine Doctors in Glenview, IL Accepting Medicare
133 Internal Medicine doctors found. Showing 121 - 133
 Dr. Alan B Shapiro, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2501 Compass Rd, Suite 130, Glenview, IL 60026 Phone: 847-677-1170 Fax: 847-677-1233 |
Dr. Johan Olof Lane, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1435 Waukegan Rd, Glenview, IL 60025 Phone: 847-832-6500 Fax: 847-724-5379 |
 Marija Nikolic, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2100 Pfingsten Rd Ste 3001a, Glenview, IL 60026 Phone: 847-657-5840 Fax: 847-657-5732 |
Dr. Undine Vallejos, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 2100 Pfingsten Rd, Glenview, IL 60026 Phone: 847-657-5800 |
Merrideth Ashley Morris, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2150 Pfingsten Rd Ste 3000, Glenview, IL 60026 Phone: 847-570-2503 |
Jared Jon Liebelt, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2150 Pfingsten Rd Ste 1200, Glenview, IL 60026 Phone: 847-864-3278 Fax: 847-657-1898 |
Westby G. Fisher, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2150 Pfingsten Rd Ste 1200, Glenview, IL 60026 Phone: 847-657-1819 Fax: 847-657-1898 |
Dr. Helen Eliopoulos, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3419 Springdale Ave, Glenview, IL 60025 Phone: 224-425-0098 |
Alfonso Bello, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2401 Ravine Way, Suite 200, Glenview, IL 60025 Phone: 847-998-5680 |
Murray James Propes, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2601 Compass Rd Ste 110, Glenview, IL 60026 Phone: 630-322-9126 |
Jose Nazari, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2150 Pfingsten Rd Ste 1200, Glenview, IL 60026 Phone: 847-657-1819 Fax: 847-657-1898 |
Dr. Eladio A Vargas, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2701 Patriot Blvd, Glenview, IL 60026 Phone: 847-724-4536 Fax: 847-998-9005 |
Dr. Jacqueline Leigh Cartier, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2701 Patriot Blvd, Glenview, IL 60026 Phone: 847-535-7647 Fax: 847-998-9733 |
News Archive
GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com
BeaconEquity.com announces an investment report featuring biopharmaceutical company Genta Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Emergent BioSolutions receives $1.25B contract to supply 44.75M doses of BioThrax
Emergent BioSolutions Inc. today announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion.
Wisconsin town offers low cost, quality care model
A Wisconsin clinic offers a better model that provides high-quality care and saves the federal government money. CQ HealthBeat reports on the Marshfield Clinic where nurses are readily available, doctors offer coordinated care to manage chronic conditions, and staff follows best practices based on convincing data.
What is the frequency of COVID testing to prevent Delta variant transmission?
In a new study published on the medRxiv* preprint server, scientists have used available data on the Delta variant's viral load to infer its infectiousness and, subsequently, estimate the reduction in its transmission brought about by surveillance testing. The testing, done at different frequencies, was performed on a susceptible population. The cases of both the original Wuhan strain and the Delta variant were considered.
Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
› Verified 2 days ago
Internal Medicine
Family Medicine
Psychiatry & Neurology
Obstetrics & Gynecology
Orthopaedic Surgery
Pediatrics
Ophthalmology
Gastroenterology
Physical Medicine & Rehabilitation
Surgery